Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study (RASTA-AF)
Atrial Fibrillation
About this trial
This is an interventional prevention trial for Atrial Fibrillation focused on measuring Risk Factor Modification, Catheter ablation
Eligibility Criteria
Inclusion Criteria:
- Patients with symptomatic (CCS-SAF ≥2) recurrent paroxysmal or persistent nonvalvular atrial fibrillation despite rate control, desiring catheter ablation AND
- one of : BMI>27, BP>140/90 or history of hypertension, alcohol use > recommended limit, current smoking, diabetes with HgA1C>7%, physical inactivity (<150 minutes/week).
(Definitions: Recurrent paroxysmal - at least 4 episodes of symptomatic AF in the prior 6 months, with or without cardioversion; Persistent AF lasting greater than 7 days but less than 3 years; AF must be documented on a Holter, rhythm strip or electrocardiogram within the last 24 months.)
Exclusion Criteria:
- Permanent AF (AF lasting > 3 years)
- Prior catheter ablation for AF
- Left ventricular ejection fraction <30%
- Left atrial size > 5.5 cm
- NYHA IV heart failure
- Participation in a cardiac rehabilitation program within the last year
- Currently performing exercise training 150 minutes/week of moderate to vigorous physical activity
- Unable to exercise
- Unable to give informed consent
- Other noncardiovascular medical condition making 1 year survival unlikely
Sites / Locations
- QE II Health Sciences Centre
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Aggressive Risk Factor Control
Standard of Care
Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.